Polysaccharide iron complex
Phase 3Small molecule
Polysaccharide iron complex is one of 64 small molecule programs targeting Coronary Artery Bypass. It is currently in Phase 3.
2
Indications
2
Total Trials
0
Active Trials
63
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
687 competitors in Heart Failure
#DrugCompanyPhaseTrials
1Polysaccharide iron complex
NNova Scotia Health Authority
Phase 3
Bayer Aspirin
BayerPreclinical
Amidate
PfizerPreclinical
Bystolic
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Zoloft
VViatris Specialty LLC
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Sulfonylureas
Eli LillyPreclinical
Thiazolidinediones
SanofiPreclinical
Alpha-Glucosidase Inhibitors
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Polysaccharide iron complex. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- NNova Scotia Health Authority